This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acquisition Of Astex Pharmaceuticals, Inc. By Otsuka Pharmaceutical Co., Ltd. May Not Be In The Best Interests Of Astex Pharmaceuticals, Inc. Shareholders

SAN DIEGO and DUBLIN, Calif., Sept. 5, 2013 /PRNewswire/ --  Shareholder rights attorneys at Robbins Arroyo LLP are investigating the acquisition of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex") by Otsuka Pharmaceutical Co., Ltd. ("Otsuka"). On September 5, 2013, the two companies announced the signing of a definitive merger agreement under which Otsuka will acquire Astex for $8.50 per share in cash.  The transaction is expected to close in the fourth quarter of 2013.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Is the Merger Best for Astex and Its Shareholders?

Robbins Arroyo LLP's investigation focuses on whether the board of directors at Astex is undertaking a fair process to obtain maximum value and adequately compensate its shareholders in the merger.  As an initial matter, the $8.50 consideration represents a premium of only 27.25% based on the Astex's closing price on September 3, 2013.  That premium is substantially below the average one-day premium of 53.13% for comparable transactions in the last three years.  Moreover, as recently as July 19, 2013, an analyst at Brean Capital, LLC set a target price of $13.00 per share, and an analyst at RBC Capital Markets set a target price of $9.00 per share on April 4, 2013.

In addition, Astex's board of directors agreed to provide additional compensation to certain company executive officers subject to consummation of the merger. This executive compensation includes a $2 million payment to Chairman of the Board and Chief Financial Officer, James Manuso; and a $253,440 payment to Astex's Chief Medical Officer, Mohammad Azab.

Given these facts, Robbins Arroyo is examining Astex's board of directors' decision to sell the company to Otsuka now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects, and whether they are seeking to benefit themselves.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs